ECP 2023 Final Programme

Tuesday, 12 Sept 59 Scientific Programme a Tuesday ECP 2023 Dublin OFP-11 Joint Oral Free Paper Session 14:45–16:45 Wicklow Hall 1 Neuropathology Ophthalmic Pathology Chairs: Robert M. Verdijk, The Netherlands Fiona Roberts, United Kingdom 001 14:45–14:55 Use of immunohistochemical surrogate biomarkers as an alternative to molecular methods in classifying adult-type diffuse gliomas Fatma Gundogdu, Turkey B. Babaoglu, F. Soylemezoglu 002 14:55–15:05 Prognostic value of the Ki-67 proliferative index in pediatric medulloblastoma, in relation to histology and molecular subgroups Mayssa Al-Hussaini, Jordan A. Abu Shanab, J. Amarin, A. Al-Ani, N. Amayiri 003 15:05–15:15 Colorectal cancer brain metastases, the use of immunohistochemistry markers in the assessment of prognosis Joao Gama, Portugal R. Caetano Oliveira, P. Teixeira, F. Silva, Â. Jesus, O. Rebelo, M. Cipriano 004 15:15–15:25 Diagnostic accuracy and feasibility of an ultra-fast digital confocal microscopy scanner for real-time intra-operative brain tumour diagnosis Richard Digby, United Kingdom W. Bolton, P. Ramakrishnan, D. Reveendran, V. Crispi, O. Adebola, R. Sinha, A. Chakrabarty, R. Mathew 005 15:25–15:35 In the molecular era, is histopathological examination still effective in demonstrating the relationship with recurrence in meningiomas? Yasemen Adali, Turkey S. Ekmekci, Ü. Küçük, Y. Pekçevik, E. Pala 006 15:35–15:45 Histologic definition of enhancing nodule and FLAIR hyperintensity region of glio- blastoma, IDH-wild type: a clinico-pathologic study on a single-institution series Giuseppe Broggi, Italy R. Altieri, V. Barresi, F. Certo, G. Barbagallo, M. Zanelli, A. Palicelli, G. Magro, R. Caltabiano 007 15:45–15:55 Neuroanatomical location of common brain metastases by primary site with assessment of provided history Michael Bonert, Canada A. Berzins, H. Begum, J. Lu, A. Swaminath, A. Naqvi 008 15:55–16:05 Characterization of the protein expression of the promising immunotherapy targets VISTA, LAG-3 and PRAME in a cohort of southern French patients with primary uveal melanoma Nuno Lamas, Portugal S. Lassalle, A. Martel, S. Nahon-Estève, A. Macocco, K. Zahaf, S. Lalvee, J. Fayada, V. Lespinet-Fabre, O. Bordone, F. Pedeutour, S. Baillif, P. Hofman 009 16:05–16:15 Prognostic significance of BAP1 protein ex- pression in uveal melanoma in comparison to The American Joint Committee on Cancer (AJCC) staging and The Cancer Genome Atlas (TCGA) system Sally Owens, Ireland C. Hegarty, N. Walsh, N. Horgan, V. O’Neill, J. O’Neill, L. Ivers, S. Kennedy 010 16:15–16:25 ATRX loss suggestive for adverse clinical behaviour in conjunctival melanocytic lesions Jolique Van Ipenburg, The Netherlands Q. van den Bosch, D. Paridaens, N. Naus, R. Verdijk 012 16:25–16:35 Prognostic risk stratification of orbital soli- tary fibrous tumours using Phosphohistone H3 (PHH3) Donna O’Dwyer, United Kingdom L. Hendrie, F. Roberts